What is peptide deamidation and why does it create impurities?
Deamidation is a non-enzymatic chemical reaction in which the side-chain amide of an asparagine or glutamine residue is hydrolysed. For asparagine, the reaction typically proceeds through a cyclic succinimide intermediate that subsequently opens to yield a mixture of aspartate and isoaspartate (iso-Asp) residues, along with possible D-isomers. Each of these species is a distinct molecular entity that differs from the parent peptide, so a single deamidation event can generate several closely related impurities. Because the reaction converts a neutral amide to a carboxylic acid, deamidation lowers the isoelectric point and shifts hydrophobicity, which is why the products are resolvable by charge- and reversed-phase-based separations. The rate is strongly sequence-dependent: Asn-Gly and Asn-Ser motifs are notably labile because the flanking residue facilitates succinimide formation, while steric bulk on the C-terminal side slows the reaction. Environmental factors including pH, temperature, buffer composition and water content all modulate the kinetics, which is why deamidation features prominently in forced-degradation and thermal-stress study designs. Comparative thermal-stress work on biologics has demonstrated that degradation profiles, including deamidation-related species, are a meaningful axis for assessing comparability between products (PMID:41011139). From a QC standpoint, deamidation matters because the resulting isoaspartate species can be nearly isobaric with the parent, meaning mass alone (a nominal +0.98 Da shift, or unresolved isomers) is insufficient — orthogonal separation and site localisation are required for a defensible impurity profile.
How is deamidation detected by RP-HPLC and peak-purity assessment?
Reversed-phase HPLC (RP-HPLC) is the primary workhorse for separating deamidation-related substances from the parent peptide. Because aspartate and isoaspartate variants differ subtly in hydrophobicity and conformation, method development focuses on maximising selectivity: shallow acetonitrile gradients, low-pH mobile phases (commonly with trifluoroacetic acid or formic acid as ion-pairing/modifier), controlled column temperature, and stationary phases with fine particle size and appropriate pore chemistry. Isoaspartate frequently elutes as a resolved shoulder or a distinct earlier- or later-eluting peak relative to the parent, and succinimide intermediates — being more hydrophobic — often elute later. A robust related-substances method reports each impurity by relative retention time (RRT) against the main peak, with system-suitability criteria fixing resolution and peak-to-valley ratios so that closely eluting deamidation species remain reliably integrated across runs. Peak-purity assessment using photodiode-array detection helps flag co-elution: spectral non-homogeneity across a peak can reveal an unresolved deamidation product hiding under the parent. However, UV spectra of Asp/iso-Asp variants are near-identical, so peak purity alone cannot confirm resolution — it is a screening tool that must be paired with orthogonal mass-spectrometric confirmation. Analysts typically validate the method with forced-degradation samples (elevated temperature and mildly basic pH) to deliberately generate deamidation products, confirming that the method can separate and detect them before it is applied to routine lot-release material. The chromatographic profile, integration parameters and RRT table then become core fields on the peptide analysis report.
How does mass spectrometry confirm and localise deamidation?
Mass spectrometry provides the identity confirmation that chromatography alone cannot. Deamidation adds a mass increment of approximately +0.984 Da per event, which is readily observed on high-resolution instruments but requires sufficient mass accuracy and resolving power to distinguish from other low-mass modifications and from natural isotope overlap. Liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS) is well established for identifying and quantifying peptide impurities, as demonstrated in detailed impurity characterisation of arginine vasopressin, where related substances were assigned and measured by LC-HRMS (PMID:32247289). To localise which residue has deamidated and to distinguish aspartate from isoaspartate, tandem mass spectrometry (MS/MS) is applied: fragment-ion ladders (b/y ions) pinpoint the modified residue, and electron-transfer or electron-capture dissociation can generate diagnostic c/z ions that help discriminate iso-Asp from Asp, since iso-Asp produces characteristic backbone fragments. Extracted-ion chromatograms of the +0.98 Da species allow the deamidation products separated by RP-HPLC to be mapped to specific masses, tying the chromatographic peak table to confirmed molecular identities. This orthogonal LC/UV + MS/MS workflow is the standard for building a defensible related-substances profile, ensuring that a peak reported as a deamidation impurity is genuinely that species and not a co-eluting synthesis by-product. The confirmed masses, charge states and fragment assignments are documented so that the peptide analysis report is traceable back to raw spectral data.
Why do relative response factors matter for quantifying deamidation impurities?
Quantifying deamidation impurities accurately is not simply a matter of area-percent on a UV chromatogram. The area-percent (or area-normalisation) approach assumes every impurity has the same UV response per unit mass as the parent peptide — an assumption that frequently fails. Deamidation products retain the same chromophores as the parent (peptide bonds and aromatic residues), so their molar absorptivity is often close to the parent, but subtle conformational and neighbouring-group effects, plus differences for succinimide intermediates, can introduce bias. The importance of applying relative response factors (RRF) for accurate impurity assessment in peptide therapeutics has been argued explicitly in the analytical literature, which highlights that ignoring RRF can systematically over- or under-state impurity levels (PMID:40499007). In practice, an RRF is determined by analysing a characterised reference of the impurity (or a spiked standard) alongside the parent and calculating the response ratio at a fixed wavelength. The reported impurity percentage is then corrected by dividing the observed area by its RRF. For deamidation species where an authentic standard is unavailable, laboratories document the assumption used (typically RRF = 1.0) transparently on the report so the researcher understands the quantification basis. Acceptance criteria for related substances are usually expressed as a maximum for any single unspecified impurity, a threshold for identified impurities, and a total-impurities limit; deamidation products above an identification threshold are named and characterised, while those below may be reported as unspecified. Clear documentation of thresholds, RRF handling and integration limits is what makes an impurity result interpretable and comparable across lots.
How is deamidation controlled through stability and stress-testing study design?
Because deamidation is time-, temperature- and pH-dependent, controlling it is largely a matter of characterising kinetics and defining appropriate storage conditions rather than eliminating a fixed defect. Forced-degradation (stress) studies deliberately accelerate deamidation — commonly by holding samples at elevated temperature and slightly elevated pH — to establish the degradation pathway, identify the resulting species, and demonstrate that the analytical method is stability-indicating (able to detect and resolve the impurities that form). Comparative stability evaluations of well-defined protein systems have shown how chemical stability, including deamidation and oxidation pathways, can be systematically mapped across variants under controlled conditions (PMID:26869420). For research peptides, a stability programme monitors related-substances profiles over time at defined storage temperatures, tracking the growth of deamidation peaks against the acceptance criteria. Lyophilised (freeze-dried) material generally shows slower deamidation than material in solution because reduced water activity limits the hydrolytic chemistry, which is one reason many research peptides are supplied lyophilised and stored cold. Reconstituted solutions are more susceptible, so reconstituted-solution stability data help define practical handling windows. Analytical comparability exercises — such as those comparing originator and biosimilar products by charge-variant and related-substances methods (PMID:30417773) — illustrate how deamidation-derived charge variants are used as a comparability marker between batches or sources. For a vendor's QC system, the practical deliverables are a validated stability-indicating method, documented stress-study data supporting the method, and a lot-release related-substances result showing the deamidation profile is within pre-set limits at dispatch.
How is deamidation reported on a peptide certificate of analysis?
On a certificate of analysis (COA) or peptide analysis report, deamidation impurities appear within the related-substances or purity section rather than as a standalone line unless they exceed an identification threshold. Typical fields include the RP-HPLC main-peak purity (area-percent), a table of individual impurities listed by RRT, the total impurities figure, and — where the laboratory has characterised specific peaks — named entries such as 'deamidated (iso-Asp/Asp) variant' with the confirming mass. The MS section reports the observed monoisotopic or average mass of the parent and any characterised impurity, allowing the reader to reconcile a +0.98 Da species with a peak in the HPLC table. A well-constructed report also states the method parameters (column, gradient, wavelength, mobile phase modifier), the system-suitability results, the RRF assumptions used for quantification, and the acceptance criteria against which the batch was assessed. When interpreting these documents, researchers should check that reported purity is chromatographic area-percent (not a marketing figure), that impurity thresholds are defined, and that any deamidation-related peaks are consistent between the chromatogram and the mass data. Cross-referencing the RRT table with extracted-ion chromatograms confirms that the analytical narrative is internally consistent. Because deamidation species can be near-isobaric and co-eluting, the presence of both orthogonal HPLC and MS data on a report is a marker of analytical rigour. Transparent documentation of these fields — with traceability back to raw instrument data and reference standards — is the foundation of defensible batch documentation for research-use material.
Apply this checklist to documented stock
You now have a practical way to read purity figures, method notes, and lot traceability. When you source materials, hold suppliers to that same checklist — ClaraScience issues batch documentation with every order and dispatches from Australian warehouses with Express tracked shipping.
Start with a retail order to review documentation end-to-end, or register for wholesale if you restock multiple compounds.
Frequently asked questions
What mass shift does deamidation produce on a mass spectrum?
Deamidation converts an amide side chain to a carboxylic acid, producing a mass increase of approximately +0.984 Da per residue affected. High-resolution mass spectrometry is needed to resolve this small shift from isotope overlap, and MS/MS is used to localise the modified residue and distinguish aspartate from isoaspartate variants (PMID:32247289).
Can HPLC alone distinguish aspartate from isoaspartate?
RP-HPLC can often separate isoaspartate and aspartate variants from the parent peptide as distinct peaks or shoulders, but their UV spectra are nearly identical, so chromatography cannot confirm identity on its own. Orthogonal mass spectrometry, including MS/MS fragment analysis, is required to confirm and localise the specific deamidation product.
Why are relative response factors important for deamidation impurities?
Area-percent quantification assumes every impurity absorbs UV identically to the parent, which is not always true. Applying relative response factors (RRF) corrects for differences in molar absorptivity, giving a more accurate impurity level. The analytical literature stresses that omitting RRF can systematically misstate impurity results in peptide products (PMID:40499007).
Which sequence motifs are most prone to deamidation?
Asparagine followed by glycine (Asn-Gly) or serine (Asn-Ser) is especially labile because the small flanking residue facilitates formation of the cyclic succinimide intermediate. Glutamine deamidates more slowly. Sequence context, pH, temperature and water content together determine the rate observed in stress and stability studies.
Does lyophilisation affect deamidation rate?
Deamidation is a hydrolytic reaction, so reduced water activity in freeze-dried (lyophilised) material generally slows it relative to peptide in solution. This is one analytical rationale for supplying and storing many research peptides in lyophilised form under cold conditions, with reconstituted-solution stability data defining practical handling windows.
References
- PMID:41011139 — Assessing the Comparability of Degradation Profiles Between Biosimilar and Originator Anti-VEGF Monoclonal Antibodies Under Thermal Stress — Pharmaceuticals (Basel) — 2025
- PMID:40499007 — The Critical Need for Implementing RRF in the Accurate Assessment of Impurities in Peptide Therapeutics — Anal Chem — 2025
- PMID:32247289 — Impurity identification and quantification for arginine vasopressin by liquid chromatography/high-resolution mass spectrometry — Rapid Commun Mass Spectrom — 2020
- PMID:30417773 — Analytical Comparison of the Originator Granulocyte-colony Stimulating Factor Filgrastim and its Biosimilars — Curr Pharm Des — 2018
- PMID:26869420 — Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms — J Pharm Sci — 2016
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
